Video

Examining Response Rates in MSI-H and NTRK Fusion GI Cancers

Author(s):

Luis A. Diaz, M.D.

Luis A. Diaz, M.D., head of the division of Solid Tumors at Memorial Sloan Kettering Cancer Center, discusses response rates in patients with microsatellite instability-high (MSI-H) or NTRK fusion gastrointestinal (GI) cancers.

Luis A. Diaz, M.D., head of the division of Solid Tumors at Memorial Sloan Kettering Cancer Center, discusses response rates in patients with microsatellite instability-high (MSI-H) or NTRK fusion gastrointestinal (GI) cancers.

Finding these biomarkers in patients with GI cancers can be particularly important, as it can help choose a treatment plan that can have a dramatic response in this group of patients.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
image of gerds
Image of 2 doctors and text.
Image of two doctors and text.
Image of man.
Image of thumbnail.
Patients can prepare personal overviews to help care teams connect with them as individuals, explained Michelle Kirschner in an interview with CURE.
Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.
Expanding on a New Way to Manage Polycythemia Vera Without Iron Deficiency
Image of woman.
Image of two people.
Related Content
Tecentriq/chemo combo reduces the risk of death vs chemo alone in dMMR, stage 3 CRC: © stock.adobe.com.
June 1st 2025

Tecentriq Plus Chemo Reduced Risk of Death vs Chemo Alone in dMMR Colon Cancer

Tony Berberabe
Tecentriq and chemotherapy combination reduces the risk of death versus chemotherapy alone in deficient mismatch repair, stage 3 colorectal cancer.
Teri Greige with medals
February 16th 2023

The Sport of Cancer: How One Survivor Linked Ironman Training and Colorectal Cancer

Brielle Benyon
Teri Griege completed an Ironman triathlon in 2009, and less than a month later received a stage 4 colorectal cancer diagnosis. In this episode of Cancer Horizons, she shared her story.
Image of intestines.
May 20th 2025

Acoustic Cluster Therapy Shows Benefit in Colorectal Liver Metastases

Spencer Feldman
Tumors shrank more with the addition of acoustic cluster therapy to chemotherapy in colorectal liver metastases in the phase 1 ACTIVATE trial.
‘Let’s Go After This Thing and Fight’ Urges a Long-Time Survivor of Early-Onset CRC
January 27th 2022

‘Let’s Go After This Thing and Fight’ Urges a Long-Time Survivor of Early-Onset CRC

Jamie Cesanek
In this episode of the “Cancer Horizons” podcast, a woman living with colorectal cancer who was diagnosed 14 years ago at age 29 discusses what it was like to be the youngest person in the treatment room, and how she found another community of young survivors.
Dr. Suresh S. Ramalingam explains that patients with stage 3 lung cancer who undergo chemotherapy and radiation may develop radiation pneumonitis.
May 7th 2025

Managing Lung Inflammation After Chemoradiation and Tagrisso

Dr. Suresh S. Ramalingam
Dr. Suresh S. Ramalingam explains that patients with stage 3 lung cancer who undergo chemotherapy and radiation may develop radiation pneumonitis.
Image of intestines
May 6th 2025

Delving Into the Braftovi Plus Erbitux FDA Approval for BRAF+ mCRC

Ryan Scott
Dr. Cathy Eng discusses data that led to the FDA approval of Braftovi and Erbitux plus chemo for metastatic colorectal cancer with a BRAF V600E mutation.